Regenxbio Inc. (RGNX) PT Raised to $40 at Stifel

Regenxbio (RGNX) Prices Upsized Public Offering of Common Stock and Pre-funded Warrants

March 6, 2024 11:40 PM EST

REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, today announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions. The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts... More

Regenxbio (RGNX) Announces Proposed Public Offering of Common Stock

March 6, 2024 4:11 PM EST

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an underwritten public offering. The offering is... More

Leerink Partners Upgrades Regenxbio Inc. (RGNX) to Outperform

March 6, 2024 6:11 AM EST

Leerink Partners analyst Mani Foroohar upgraded Regenxbio Inc. (NASDAQ: RGNX) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on Regenxbio Inc. click here. For more ratings news on Regenxbio Inc. click here.

Shares of Regenxbio Inc. closed at $24.61 yesterday.

... More

Regenxbio Inc. (RGNX) PT Raised to $39 at Baird

March 5, 2024 4:27 PM EST

Baird analyst Brian Skorney raised the price target on Regenxbio Inc. (NASDAQ: RGNX) to $39.00 (from $34.00) while maintaining an Outperform rating.

The analyst commented, "The first patient at dose level 2 of RGX-202 showed 76% expression and solid CK reduction, and we walk away... More

Regenxbio (RGNX) Climbs 30% Following New Positive Initial Efficacy Data From Affinity Duchenne Trial

March 5, 2024 7:42 AM EST

Regenxbio (NASDAQ: RGNX) Climbs 30% Following New Positive Initial Efficacy Data From Affinity Duchenne Trial

New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expressionPatient aged 12 years at dosing had expression level at 75.7% of controlEarly evidence of strength and... More

Regenxbio (RGNX) Announces New Positive Initial Efficacy Data for RGX-202

March 5, 2024 7:05 AM EST

REGENXBIO Inc. (Nasdaq: RGNX) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old, including RGX-202 microdystrophin expression from dose level 2 and video of trial clinic assessments demonstrating initial evidence of strength and functional improvement.

"RGX-202 at dose level 2 is demonstrating significantly increased microdystrophin expression in a 12-year-old patient," said Kenneth T. Mills, President and CEO, REGENXBIO.... More